2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-cyclobutyl-pyrimidine | 876028-62-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-cyclobutyl-pyrimidine
• 英文别名: 2-tert-butyl-4-[4-(3-chloropropyl)piperazin-1-yl]-6-cyclobutylpyrimidine
• CAS: 876028-62-5
• 化学式: C₁₉H₃₁ClN₄
• 分子量: 350.935
• InChiKey: OSQZGYDKHRKUAD-UHFFFAOYSA-N

物化性质

• 沸点：
  480.1±45.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-cyclobutyl-pyrimidine 、 2-巯基-1,3,4-噻二唑 在 lithium hydroxide 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 2-tert-butyl-4-cyclobutyl-6-{4-[3-([1,3,4]thiadiazol-2-ylsulfanyl)-propyl]-piperazin-1-yl}-pyrimidine
  参考文献：
  名称：

  [EN] 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
  [FR] COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE

  摘要：

  本发明涉及新颖的4-哌嗪基嘧啶化合物。这些化合物具有有价值的治疗特性，特别适用于治疗对多巴胺D3受体调节产生反应的疾病。4-哌嗪基嘧啶化合物具有通式(I)，其中Ar、X、A、R1和R1a如权利要求中所定义。

  公开号：

  WO2006015842A1
• 作为产物：
  描述：

  2-tert-butyl-4-(piperazin-1-yl)-6-cyclobutyl-pyrimidine 、 1-溴-3-氯丙烷 在 四丁基溴化铵 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 5.0h， 以91%的产率得到2-tert-butyl-4-[4-(3-chloro-propyl)-piperazin-1-yl]-6-cyclobutyl-pyrimidine
  参考文献：
  名称：

  [EN] 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
  [FR] COMPOSÉS DE 4-PIPÉRAZINYLPYRIMIDINE CONVENANT POUR TRAITER DES TROUBLES QUI RÉPONDENT À UNE MODULATION DU RÉCEPTEUR D3 DE LA DOPAMINE

  摘要：

  本发明涉及新颖的4-哌嗪基嘧啶化合物。这些化合物具有有价值的治疗特性，特别适用于治疗对多巴胺D3受体调节产生反应的疾病。4-哌嗪基嘧啶化合物具有通式(I)，其中Ar、X、A、R1和R1a如权利要求中所定义。

  公开号：

  WO2006015842A1

文献信息

• 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
  申请人：Haupt Andreas

  公开号：US20090264437A1

  公开（公告）日：2009-10-22

  The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D 3 receptor. The 4-piperzinylpyrimidine compounds have the general formula I wherein Ar, X, A, R 1 and R 1a are as defined in the claims.

  本发明涉及新型4-哌嗪基嘧啶化合物。这些化合物具有有价值的治疗性质，特别适用于治疗对多巴胺D3受体调节有反应的疾病。4-哌嗪基嘧啶化合物具有一般式I，其中Ar、X、A、R1和R1a如权利要求中所定义。
• Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
  申请人：Unger Liliane

  公开号：US20080171751A1

  公开（公告）日：2008-07-17

  The invention relates to compounds of the formula I: wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms; R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R 1a is hydrogen or C 1 -C 4 alkyl; and R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

  该发明涉及公式I的化合物：其中n为1或2，Ar为C-结合的1,2,4-三唑基团，在剩余碳原子上携带基团R1，并在其中一个氮原子上携带基团R1a；R1为氢、C1-C6烷基、C3-C6环烷基、C1-C4烷氧甲基、氟化C1-C6烷基、氟化C3-C6环烷基、氟化C1-C4烷氧甲基或可选取代的苯基或5-或6-成员杂环基；R1a为氢或C1-C4烷基；R2为C1-C6烷基、C3-C6环烷基、氟化C1-C6烷基或氟化C3-C6环烷基；以及这些化合物的生理耐受性酸加盐物。该发明还涉及一种制备至少一种公式I的三唑化合物和/或至少一种生理耐受性酸加盐物的制药组合物，以及一种治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病的方法，该方法包括向需要治疗的受体中给予至少一种公式I的三唑化合物或生理耐受性酸加盐物的有效剂量。
• Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
  申请人：Abbott GmbH & Co. KG

  公开号：US08101754B2

  公开（公告）日：2012-01-24

  The invention relates to compounds of the formula I: wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C4 alkoxymethyl, or optionially substituted phenyl or 5- or 6-membered heteroaryl; R1a is hydrogen or C1-C4 alkyl; and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C6 alkyl or fluorinated C3-C6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

  本发明涉及式I的化合物：其中n为1或2，Ar为C-键结的1,2,4-三唑基团，其在剩余碳原子上携带基团R1，在其中一个氮原子上携带基团R1a；R1为氢、C1-C6烷基、C3-C6环烷基、C1-C4烷氧甲基、氟代C1-C6烷基、氟代C3-C6环烷基、氟代C1-C4烷氧甲基或可选取代的苯基或5-或6-成员杂环基；R1a为氢或C1-C4烷基；R2为C1-C6烷基、C3-C6环烷基、氟代C1-C6烷基或氟代C3-C6环烷基；以及这些化合物的生理耐受性酸盐。本发明还涉及一种制药组合物，其包含式I的至少一种三唑化合物和/或至少一种生理耐受性酸盐，并且还涉及一种治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病的方法，该方法包括将至少一种式I的三唑化合物或其生理耐受性酸盐的有效量给予需要的受试者。
• TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
  申请人：Unger Liliane

  公开号：US20120095015A1

  公开（公告）日：2012-04-19

  The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms; R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R 1a is hydrogen or C 1 -C 4 alkyl; and R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceutically composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.

  本发明涉及式（I）的化合物，其中n为1或2，Ar是C-连接的1,2,4-三唑基团，其在剩余碳原子上带有基团R1，并在其中一个氮原子上带有基团R1a；R1为氢，C1-C6烷基，C3-C6环烷基，C1-C4烷氧甲基，氟代C1-C6烷基，氟代C3-C6环烷基，氟代C1-C4烷氧甲基，或者可选取代的苯基或5-或6-成员杂环基；R1a为氢或C1-C4烷基；R2为C1-C6烷基，C3-C6环烷基，氟代C1-C6烷基或氟代C3-C6环烷基；以及这些化合物的生理耐受性酸加成盐。本发明还涉及一种制药组合物，其包括至少一种式（I）的三唑化合物和/或至少一种其生理耐受性酸加成盐，以及一种用于治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病的方法，该方法包括向需要的受体中注射至少一种三唑化合物或式（I）的生理耐受性酸加成盐的有效量。
• 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
  申请人：Abbott GmbH & Co. KG

  公开号：US08202868B2

  公开（公告）日：2012-06-19

  The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. The 4-piperzinylpyrimidine compounds have the general formula I wherein Ar, X, A, R1 and R1a are as defined in the claims.

  本发明涉及新型的4-哌嗪基嘧啶化合物。这些化合物具有有价值的治疗特性，特别适用于治疗对多巴胺D3受体调节反应的疾病。4-哌嗪基嘧啶化合物的一般式为I，其中Ar，X，A，R1和R1a如权利要求所定义。